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OBJECTIVES We studied associations between iron status and early functional and structural vascular
abnormalities in patients with hereditary hemochromatosis (HH).
BACKGROUND Iron may be involved in atherogenesis, and patients bearing a genetic mutation associated
with HH are possibly at risk of developing coronary heart disease.
METHODS We studied the vascular properties of 41 HH patients who had homozygosity for the C282Y
mutation, along with 51 age-matched control subjects, by determination of endothelium-
dependent dilation (EDD) of the brachial artery and intima-media thickness (IMT) of the
carotid artery.
RESULTS Male HH patients who were not receiving phlebotomy therapy showed a reduced EDD and
increased IMT compared with controls and HH patients receiving therapy. In female HH
patients, irrespective of treatment status, vascular parameters were not different from those of
controls, and none of these patients had severe iron overload. In HH patients, increased iron
load was significantly associated with reduced EDD and increased IMT. Moreover, we found
a positive correlation between body iron stores and indicators of oxidative stress. When
previously untreated male HH patients were re-investigated after intensive phlebotomy
therapy, a significant improvement in EDD was observed (2.6  1.3% before vs. 5.5  2.1%
after treatment, p  0.0015).
CONCLUSIONS Impaired endothelial function and increased IMT are associated with iron overload, with
subsequent induction of oxidative stress, and are not linked to a genetic disability in HH
patients. Consequent iron-depletion therapy normalizes endothelial function and may thus
reduce the increased risk of cardiovascular events. Female patients may be at a reduced risk,
presumably due to continuous iron loss by menstruation. (J Am Coll Cardiol 2002;40:
2189–94) © 2002 by the American College of Cardiology Foundation
Iron is a transition metal that catalyzes the formation of
reactive oxygen species (ROS) by the Fenton reaction (1).
Oxygen radical formation and subsequent lipid peroxidation
are postulated to be involved in the pathogenesis of athero-
sclerosis (2). Several epidemiologic studies have investigated
the role of iron as a potent risk factor in coronary heart
disease (CHD) (3–9). Elevated stores of iron in the body
were associated with an increased risk of CHD-related
death or myocardial infarction (MI) in some (3–5) but not
all (6–9) studies. Recent studies in subjects heterozygous for
a cysteine-to-tyrosine mutation at amino acid position 282
(C282Y) within the hemochromatosis gene (HFE), associ-
ated with hereditary hemochromatosis (HH), identified
those persons to be at an increased risk of cardiovascular
death and MI (10,11).
An increased intima-media thickness (IMT) of carotid
arteries has proven to be a reliable marker reflecting early
structural vascular pathology associated with cardiovascular
risk factors and CHD prevalence (12). Despite impressive
correlations between increased body iron stores and early
atherosclerotic lesions in some studies (13,14), another
report failed to confirm this association (15). Endothelial
dysfunction, preceding the appearance of structurally evi-
dent atherosclerosis, has been recognized as an important
early functional abnormality in atherogenesis (16) and
accepted as a surrogate marker of vascular pathology leading
to atherosclerosis (17).
In patients with iron overload due to HH, these func-
tional and structural markers of increased cardiovascular risk
had not been assessed thus far. To this aim, we investigated
in the present study the inter-relationship between brachial
artery endothelial function and early structural changes in
carotid arteries, and parameters of iron overload and oxida-
tive stress in HH subjects with and without iron-depletion
therapy, along with age- and gender-matched controls.
METHODS
Subjects. From a list of 1,797 subjects genotyped for the
C282Y and H63A mutations of the HFE gene, according to
Simonsen et al. (18) at the Department of Internal Medi-
cine in Innsbruck, Austria, between March 1996 and
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December 1999, we found 119 of these patients to be
homozygous for the C282Y mutation. These subjects were
invited to participate in this study. Of 105 subjects who
were willing to participate, 64 were excluded because they
met at least one of the following criteria: age 65 or 18
years, clinical evidence of HH-related advanced disease
(e.g., liver cirrhosis, cardiomyopathy, diabetes mellitus) or
cardiovascular disease, and any type of medical treatment,
including intake of anti-oxidant agents. Presence of cardio-
vascular disease was determined by taking a history, physical
examination, and rest electrocardiogram (ECG); presence
of diabetes mellitus was determined by measuring fasting
plasma glucose. Subjects homozygous or heterozygous for
the H63A mutation of the HFE gene were excluded, as the
clinical role of this mutation in the pathophysiology of HH
is not very well understood (19). Fifty-one healthy subjects
matched for age, gender, blood pressure, body mass index,
and nicotine consumption, recruited from hospital staff
members, served as control subjects. None of the control
subjects was either homozygous or heterozygous for the
respective HH-associated HFE mutations, C282Y or
H63A. All participants gave written, informed consent.
This study conformed to the principles outlined in the
Declaration of Helsinki.
Study protocol. Blood samples were drawn after an over-
night fast and 12-h abstinence from smoking. Thereafter,
all subjects were given a typical continental breakfast and
refrained from further food intake and smoking. At 1:00 PM,
vascular studies were performed after taking a medical
history and measuring resting pulse and blood pressure in
subjects in a supine position.
Previously untreated patients with HH were subjected to
regular phlebotomy, according to standard guidelines (20),
after the baseline examination and were re-examined after
three to six months of therapy.
Brachial artery study. Endothelium-dependent and
-independent dilation (EDD and EID, respectively) of the
brachial artery were determined as described by Celermajer
et al. (17). In brief, this vessel was scanned 2 to 15 cm above
the elbow with the use of a 13.0-MHz, linear-array trans-
ducer and a standard Acuson Sequoia 512 system (Acuson,
Mountain View, California). After recording a rest scan, a
pneumatic cuff was placed around the forearm and inflated
to a pressure of 250 mm Hg for 4.5 min. Pressure release
resulted in reactive hyperemia, which is the stimulus for
flow-mediated EDD. A scan of the brachial artery was
performed within 45 to 90 s after cuff deflation. Thereafter,
a period of 10 min was allowed for recovery of the vessel.
Sublingual glyceryl trinitrate was then administered (400
g) to induce EID, and 3 to 4 min later the scan was taken.
The vessel diameter was measured by two independent
investigators who were unaware of the subjects’ clinical
details and stage of study. The technique for diameter
measurement was highly reproducible in our laboratory and
showed a coefficient of variation of 3%, based on mea-
surements taken from the same subjects on separate days
(21). Both EDD and EID were determined as the percent-
age of diameter change relative to the mean value of the
corresponding baseline measurements.
Carotid artery study. Longitudinal B-mode scans of the
common carotid artery were obtained immediately after the
studies of brachial artery reactivity, using the same ultra-
sound system and a 9.0-MHz, linear-array transducer. The
far wall was assessed just proximal to the carotid bifurcation
(last 2 cm) to identify the maximal IMT, defined as the
distance between the junction of the lumen and intima and
that of the media and adventitia (12). Three measurements
were made in the right and left carotid arteries and were
averaged to determine the IMT for each side.
Chemical analyses. Thiobarbituric acid–reactive substance
(TBARS) levels in the serum samples were measured
spectrophotometrically at 535 nm, exactly as described by
Buege and Aust (22), using 1,1,3,3,-tetramethoxypropane
(Sigma Chemical Co., Munich, Germany) as a standard.
Plasma levels of total cholesterol, low-density and high-
density lipoprotein cholesterol, and triglycerides were mea-
sured by standard automated enzymatic or turbimetric
assays. Serum iron was measured by a ferrozine-based
spectrophotometric assay; the transferrin concentration by a
turbimetric method; and ferritin by an enzyme-linked im-
munosorbent assay (23). Glutathione levels in plasma were
determined by means of a commercially available assay
(Calbiochem, Darmstadt, Germany) with a detection limit
of 5 mol/l. Ferroxidase activity was measured as a param-
eter of increased iron turnover and measured spectrophoto-
metrically, according to Erel (24).
Statistical analysis. Analyses were performed by using the
statistical software package SYSTAT, version 7.01 (SPSS,
Chicago, Illinois). Continuous variables were compared by
using the Student t test. Proportions were compared by
using the Fisher exact test. Because iron parameters (fer-
ritin) followed skewed rather than gaussian distributions,
they were also evaluated by non-parametric statistical anal-
yses (Kruskal-Wallis), and a Bonferroni correction was
applied when p values were calculated. Correlations among
various measures were assessed by the Spearman rank
correlation technique.
Abbreviations and Acronyms
CHD  coronary heart disease
EDD  endothelium-dependent dilation
EID  endothelium-independent dilation
HFE  hemochromatosis gene
HH  hereditary hemochromatosis
IMT  intima-media thickness
MI  myocardial infarction
NO  nitric oxide
ROS  reactive oxygen species
TBARS  thiobarbituric acid–reactive substances
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RESULTS
Baseline clinical and laboratory data. Of the 41 HH
subjects investigated, 25 were already receiving phlebotomy
therapy at study entry, whereas 16 were untreated. Male
patients receiving therapy had significantly more phleboto-
mies performed per year than female patients (Table 1). The
baseline clinical and biochemical characteristics of control
subjects and treated and untreated HH patients are shown
in Table 1, with separate analyses for men and women. As
expected, parameters of iron overload were higher in sub-
jects with HH compared with controls and revealed impres-
sive differences when comparing male and female groups.
Untreated male HH patients showed a higher level of iron
overload than male patients already receiving phlebotomy
treatment at study entry, a difference that was not evident
between untreated and treated female HH patients. We also
determined fasting plasma glucose and glycosylated hemo-
globin, but no differences were found between the respective
groups (details not shown).
Serum levels of TBARS were significantly higher in HH
patients compared with controls, irrespective of gender, but
again, the levels were highest in untreated male patients.
Reduced levels were also observed for the radical scavenger
glutathione in subjects with HH compared with controls.
Baseline vascular characteristics. Brachial artery EDD
was significantly reduced in untreated male HH patients
compared with controls and treated HH patients, with no
difference between treated HH patients and controls (Table
2). In women, no difference in EDD was observed between
HH patients and controls, irrespective of treatment status.
Baseline vessel diameter, baseline blood flow, reactive hy-
peremia, and EID were not different between HH patients
and controls, for both genders. An increased IMT of the
common carotid artery was observed in untreated male HH
patients compared with controls and treated patients. In
women, no differences in IMT were observed between the
different groups.
Changes in clinical, laboratory, and vascular parameters
after phlebotomy in previously untreated hemochroma-
totic patients. Among the 41 HH patients studied, 10
male and 6 female individuals were not yet receiving
phlebotomy treatment at study entry. Although none of
these female patients had evidence of severe iron overload in
serum, which would have justified the initiation of regular
phlebotomy treatment, all male patients had severe iron
overload and were assigned to treatment with intensive
phlebotomy. Furthermore, Tables 1 and 2 show the effect of
phlebotomy therapy on the clinical, biochemical, and vas-
cular characteristics of these 10 male HH patients. Not
surprisingly, parameters of iron overload (e.g., ferritin, iron,
transferrin saturation) were reduced after phlebotomy ther-
apy. Moreover, in parallel, we found that TBARS became
Table 1. Baseline Clinical and Biochemical Characteristics in Treated and Untreated Patients With Hereditary Hemochromatosis and
Control Subjects
Control Subjects Treated Patients With HH
Untreated Patients
With HH
Women
(n  6)
Men
(n  10)
Women
(n  14)
Men
(n  37)
Women
(n  6)
Men
(n  19)
Before
Phlebotomy
After
Phlebotomy
Age (yrs) 32.0  8.4 40.1  10.0 38.3  11 42.3  12.5 33.5  12.5 43.5  10.1 43.8  10.1
Body mass index (kg/m2) 21.7  1.9 24.9  2.9 23.9  6.1 25.2  2.7 22.5  3.7 24.5  2.7 25.2  3.8
Smokers 0 5 (13.5%) 0 3 (15.8%) 0 1 (10.0%) 1 (10.0%)
Systolic BP (mm Hg) 122  9 122  11 117  13 123  12 119  12 125  11 124  12
No. of phlebotomies in
previous year
0 0 1.9  1.5 6.4  3.0 0 0 9.4  2.6
Hematocrit (ml/dl) 44  1 44  2 43  2 44  3 41  2 45  2 42  3¶
Hemoglobin (g/l) 145  5 150  7 149  8 150  8 140  7 155  9 142  12#
Total cholesterol (mg/dl) 196  23 202  41 219  60 188  36 176  13 192  32 183  19
LDL cholesterol (mg/dl) 97  22 122  37 129  61 117  66 92  22 101  31 108  27
HDL cholesterol (mg/dl) 77  13 54  14 67  19 58  16 69  15 56  16 54  15
Triglycerides (mg/dl) 111  55 134  74 111  44 143  78 102  28 190  11 124  35
Serum ferritin (g/l) 29  18 72  50 111  92 190  208* 79  88 1,640  778†§ 684  700¶
Transferrin saturation (%) 26.9  14.6 26.5  12.8 54.2  27.2* 60.9  24.3† 53.7  9.9† 93.9  2.6†§ 63.2  37.8**
Serum iron (mol/l) 20.1  8.2 18.5  7.3 26.2  10.5 29.2  9.0† 28.3  6.5‡ 38.6  6.2† 22.0  12.1**
Ferroxidase activity (U/l) 893  171 834  182 840  210 992  103† 893  66 961  70* 912  66
TBARS (mol/l) 0.66  0.13 0.73  0.13 1.00  0.23* 0.80  0.14‡ 0.90  0.21‡ 1.12  0.31† 0.98  0.35**
Glutathione (mol/l) 107.3  50.7 45.0  38.3 33.9  37.8 42.1  55.4 29.7  12.7 29.8  34.0 38.4  27.5
*p  0.01, †p  0.001, and ‡p  0.05 versus corresponding male or female control subjects. §p  0.001 and p  0.01 for untreated versus treated patients with HH. ¶p 
0.001, **p  0.05, and #p  0.01 for untreated male patients before versus after phlebotomy therapy. Data are presented as the mean value  SD or number (%) of patients
or control subjects.
BP  blood pressure; HDL  high-density lipoprotein; HH  hereditary hemochromatosis; LDL  low-density lipoprotein; TBARS  thiobarbituric acid–reacting
substances.
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significantly ameliorated with iron-depletion therapy. Dur-
ing therapy, hemoglobin concentrations and hematocrit
levels declined, but no patient became anemic.
Most interestingly, EDD significantly improved after
phlebotomy therapy and was, at this time, not different from
that of previously treated HH subjects and even controls
(Tables 1 and 2, respectively). All other vascular parameters,
including IMT, did not change within this observation
period.
Inter-relationship between vascular parameters, iron me-
tabolism, and oxidative stress. To see whether EDD,
IMT, iron burden, and oxidative stress are in a relationship
together, we calculated Spearman rank correlations among
these respective parameters (Table 3). When investigating
treated HH patients, untreated HH patients, and controls
separately, the correlations among the parameters remained
the same within all groups (details not shown).
Table 3, showing the results obtained in all HH patients,
suggests that increased iron burden, as estimated by higher
ferritin levels and transferrin saturation, is associated with
impaired EDD and increased IMT. In contrast, neither
hemoglobin nor hematocrit showed a significant relation-
ship to EDD or IMT.
Moreover, impaired EDD and increased IMT were
correlated with TBARS levels, and this association was even
more pronounced when investigating all subjects (both
controls and HH patients), which can be related to the
higher number of individuals (n  92) involved in this
analysis (p  0.003 for EDD and TBARS; p  0.064 for
IMT and TBARS). As a parameter of oxidative stress,
TBARS was also positively associated with increased iron
concentrations in serum (Table 3), again with the correla-
tion being more significant when the analysis included all
subjects participating in the study (p 0.001 for ferritin and
TBARS; p  0.001 for transferrin saturation and TBARS).
Finally, IMT was inversely related to EDD.
DISCUSSION
Our study shows that endothelial function is impaired in
HH patients with profound iron overload. Because reduced
EDD was closely associated with increased levels of ferritin
and transferrin saturation, we consider that endothelial
dysfunction is linked to iron overload. This assumption is
supported by various findings of our study.
First, untreated male HH patients with excessive iron
overload were the only group with EDD impairment.
Second, we found that a reduction in iron burden by
Table 2. Baseline Vascular Characteristics in Treated and Untreated Patients With Hereditary Hematochromatosis and Control
Subjects
Control Subjects
Treated Patients With
HH
Untreated Patients With HH
Women
(n  6)
Men
(n  10)
Women
(n  14)
Men
(n  37)
Women
(n  6)
Men
(n  19)
Before
Phlebotomy
After
Phlebotomy
Functional measures of the brachial artery
Baseline diameter (mm) 3.8  0.4 4.5  0.5 3.6  0.3 4.8  0.6 3.9  0.3 4.5  0.5 4.6  0.3
Baseline blood flow (ml/s) 138  19 141  32 138  52 136  43 145  29 145  50 132  55
Reactive hyperemia (%) 389  71 384  76 443  76 420  99 353  43 409  47 398  38
EDD (%) 8.9  5.5 6.2  3.2 6.6  2.4 5.2  2.9 8.9  1.1 2.6  1.3*† 5.5  2.1¶
EID (%) 21.1  6.1 14.9  4.3 19.6  4.8 14.5  6.1 21.7  4.5 12.9  5.1 12.4  2.6
Structural measures of the common carotid artery
Intima-media thickness (mm)
Right artery 0.41  0.05 0.55  0.12 0.47  0.07 0.56  0.16 0.46  0.07 0.68  0.08‡§ 0.68  0.07
Left artery 0.44  0.06 0.57  0.14 0.48  0.06 0.58  0.20 0.43  0.09 0.71  0.15 0.71  0.13
Combined arteries 0.42  0.05 0.56  0.13 0.47  0.05 0.57  0.18 0.45  0.08 0.70  0.11§ 0.70  0.10
*p  0.001, ‡p  0.01, and p  0.05 versus corresponding male or female control subjects. †p  0.01 and §p  0.05 for untreated versus treated patients with HH. ¶p  0.001
for untreated male patients before versus after phlebotomy therapy. Data are presented as the mean value  SD.
EDD  endothelium-dependent dilation; EID  endothelium-independent dilation; HH  hereditary hemotochromatosis.
Table 3. Inter-relationship Between Serum Concentrations of Iron Metabolism Parameters,
Oxidative Stress, and Endothelial Function in Patients With Hereditary Hematochromatosis
Ferritin TS TBARS EDD IMT
TS 0.664 (0.001) —
TBARS 0.455 (0.03) 0.389 (0.07) —
EDD 0.730 (0.001) 0.530 (0.004) 0.382 (0.07) —
IMT 0.544 (0.002) 0.403 (0.06) 0.316 (NS) 0.617 (0.001)
Hct 0.261 (NS) 0.183 (NS) 0.217 (NS) 0.267 (NS) 0.300 (NS)
Data are presented as correlation coefficients with p values (Bonferroni-corrected) in parentheses. NS  not significant at p 
0.1. The results for patients with hereditary hemochromatosis, irrespective of therapy status, are shown (n  41).
EDD  endothelium-dependent dilation; Hct  hematocrit; IMT  intima-media thickness; TBARS  thiobarbituric
acid–reacting substances; TS  transferrin saturation.
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initializing phlebotomy therapy in previously untreated male
HH patients led to both a reduction in the parameters of
iron overload and a significant improvement of endothelial
function. Third, EDD was not impaired in male HH
patients treated with phlebotomy at study entry; they
demonstrated only moderate iron overload at this time.
Fourth, in females, we were unable to reveal any difference
in endothelial function between controls and HH patients,
irrespective of treatment with phlebotomy. This is in
agreement with the observation that even untreated women
with HH have an almost balanced iron status, which could
be explained, in part, by the fact that there is an additional
iron loss in women due to menstruation. This notion is
supported by the finding of significantly less phlebotomies
per year in women compared with men.
Endothelium-independent dilation induced by applica-
tion of the exogenous nitric oxide (NO) donor glyceryl
trinitrate, and considered to reflect vascular responsiveness
independent of endogenous NO production, was unaffected
in patients with HH. Thus, iron impairs EDD by modu-
lating endothelial function. Although iron can reduce the
formation of NO in the endothelium (25), thereby affecting
endothelial dilation, it is more likely that impaired EDD in
iron overload is linked to the capacity of the metal to
catalyze the formation of ROS by the Haber-Weiss reaction
(1). This leads to oxidative stress, as reflected by our finding
of an association between increased TBARS and reduced
glutathione levels with iron overload and impaired EDD,
which is also confirmed by a recent report studying the
effects of iron infusion on EDD (26). Oxidative stress may
cause lipid peroxidation (2) or lead to impairment of
endothelium-dependent signaling processes (1,27), with a
subsequent reduction of endothelial relaxation.
Endothelium-dependent dilation could be improved after
phlebotomy therapy in previously untreated patients (Tables
1 and 2) or by application of the iron chelator deferoxamine
in patients with CHD (28). Thus, endothelial function is
not generally impaired in patients with HH as a function of
genetics, as determined by mutations within the HFE gene,
but rather is a consequence of iron overload (29). From our
calculations, it is further suggestive that EDD is primarily
influenced by iron burden and not directly by hemoglobin or
hematocrit (Table 3).
We found an association between iron overload and early
structural atherosclerotic changes, as reflected by increased
IMT in the group of previously untreated male HH
patients. In contrast, in patients receiving phlebotomy
therapy and in women, IMT was not significantly different
from that of controls. Thus, prolonged iron overload and
subsequent oxidative stress may ultimately result in in-
creased IMT, but consequent iron-depletion therapy may
prevent the development of early atherosclerotic changes. A
recent study indicated that prolonged and consequent iron-
depletion therapy may reduce previously increased radial
artery wall thickness in subjects with HH (30), which could
not be confirmed by our study within a short treatment
period of three months.
Because impaired EDD and increased IMT reflect early
functional and structural abnormalities in atherogenesis and
are thus accepted as surrogate indicators of an increased
cardiovascular risk (12,17), our data support the hypothesis
that iron is a risk factor of CHD. In 1981, Sullivan (31)
proposed that the difference in the incidence of CHD
between man and women could be explained by differences
in stored iron. He argued that the physiologic blood loss by
menstruation represents the underlying mechanism for pro-
tective iron depletion. Consequently, iron depletion by
regular blood loss decreases the risk of MI (32), whereas
iron supplementation, especially in patients with renal
disease, is associated with severe coronary events (33).
However, data on the risk of CHD in subjects with iron
overload are conflicting and contradictory (3–9,13–15).
From our data showing a linkage of EDD and IMT to iron
overload, but not to the C282Y mutation of the HFE gene,
it is suggestive that one reason for the conflicting data
among these studies is that the patients investigated were
heterogeneous in terms of iron burden and effectiveness of
iron-depletion therapy (34).
Study limitations. The number of untreated HH patients
investigated was small. This bears the potential bias of
results by a few outliers and chance findings. However, even
when comparing the small number of untreated male
patients before and after phlebotomy therapy, we found
significant differences with both parametric and non-
parametric tests, even with a Bonferroni correction. We
were unable to recruit untreated female subjects with severe
iron overload, and we did not study postmenopausal women
with or without HH. Thus, we cannot provide information
on the chances of EDD and IMT and their relationship to
iron overload in such patients. Our study also had the
limitation that the intervention portion of the previously
untreated patients was not randomized. We used indirect
indicators of oxidative stress to verify the inter-relationship
between iron, oxidative stress, and endothelial dysfunction.
Although the TBARS assay lacks some specificity to reflect
lipid peroxidation, it is a widely used method to monitor
oxidative stress. Moreover, our TBARS level findings are
supported by our measurement of glutathione levels, which
followed iron-modulated changes in a similar way. Finally,
we cannot rule out the contribution of environmental
influences or genetic backgrounds, other than HFE muta-
tions, to endothelial function or handling of iron or detox-
ification of radicals within the body. Although we have good
evidence pointing to the cause-effect relationship between
iron and EDD, we cannot rule out that factors other then
modulation of iron homeostasis may be influenced by
phlebotomy therapy, thus altering EDD. Moreover, it is
also possible that the effect of iron on EDD is indirect, as
iron may alter immune function, oxidative phosphorylation,
NO production, susceptibility to infections, or the availabil-
ity and function of micronutrients and vitamins (35,36).
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Conclusions. Our results demonstrate that impaired EDD
and increased IMT in untreated male HH patients are due
to excessive iron overload and are not linked to a genetic
disability. Endothelial dysfunction may be a reflection of
iron induced oxidative stress, with both parameters improv-
ing with induction of iron-depletion therapy by phlebot-
omy. Whether the change in endothelial function may
indeed reduce the risk of cardiovascular events has to be
verified by prospective, randomized clinical studies.
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